Cholangiocarcinoma
Cholangiocarcinoma (CCA), a rare and aggressive form of cancer, has seen a steady increase in incidence in the United States, with a predominant increase in intrahepatic CCA, from 2001 to 2017, according to a recent epidemiological study. Read More ›
At the 4th Annual Cholangiocarcinoma Summit, held on October 13-15, 2022, experts in the field of gastroenterology, interventional radiology, nursing, and surgery discussed the importance of using a multidisciplinary approach to supportive care and the management of complications in patients with biliary tract cancers (BTCs). Read More ›
On October 21, 2022, the FDA approved tremelimumab (Imjudo; AstraZeneca), a CTLA-4 monoclonal antibody, in combination with durvalumab (Imfinzi; AstraZeneca), a PD-L1 inhibitor, for the treatment of adults with unresectable hepatocellular carcinoma (HCC). Read More ›
A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters. Read More ›
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma. Read More ›
Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control. Read More ›
The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer. Read More ›
The combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin was shown to be promising as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer in this phase 2 study. Read More ›
Study revealed increased financial toxicities in patients with cholangiocarcinoma enrolled in clinical trials and receiving targeted therapies. Read More ›
Erdafitinib was found to be associated with durable efficacy and manageable toxicity in Asian patients with advanced cholangiocarcinoma with FGFR alterations. Read More ›